For nearly two decades, I have relied on Cymbalta, a medication developed by Eli Lilly, to manage my depression and anxiety. This drug has been a lifeline for me, banishing the dark clouds of despair that often shroud my world. Tragically, Eli Lilly has chosen to discontinue Cymbalta, leaving countless patients in a difficult position.

Generic alternatives simply do not equate to the effectiveness and stability that Cymbalta has consistently provided. For me personally, trying a generic substitute led to a serious regression in my mental well-being. I am not alone in this experience; many others have shared similar stories.

Eli Lilly has produced Cymbalta for years, standing as a beacon of hope for those battling depression, generalized anxiety disorder, fibromyalgia, and other conditions. An estimated 10.6 million prescriptions for Cymbalta were filed in the U.S alone in 2016, showcasing the vital need for this medication (IMS Health Data, 2016).

It is crucial to remember that for many, access to effective medication is not just about alleviating symptoms; it’s a matter of survival.

Eli Lilly, we are aware that business decisions necessitate cost-cutting maneuvers. But we urge you to consider the human cost. By taking away Cymbalta, you are snatching away a vital pillar of support for millions world-wide who combat, daily, the profound effects of mental health disorders. 

Please reconsider the decision to discontinue Cymbalta.

Now, we ask for your support. Sign this petition. Stand with us, and with millions of others in need.